Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing

For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE(®)), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Ross, Sandra L., Sherman, Marika, McElroy, Patricia L., Lofgren, Julie A., Moody, Gordon, Baeuerle, Patrick A., Coxon, Angela, Arvedson, Tara
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570333/
https://ncbi.nlm.nih.gov/pubmed/28837681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0183390
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados